The impact of biological interventions on health-related quality of life in adults with Crohn's disease

The impact of biological interventions on health-related quality of life in adults with Crohn's disease

Crohn disease is a very aggressive inflammatory gastrointestinal disease which substantially decrease health-related quality of life in patients. Different strategies are involved to influence on disease course (surgery, drug treatment). Biologic drugs represent a revolution in this field of medicine decreasing disease symptoms. The aim of this study is to examine if biologicals could influence on health-related quality of life which represent a final goal for the patients.

[{ "PostingID": 2348, "Title": "TAKEDA-C13007", "Description": "A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission by Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease" },{ "PostingID": 2349, "Title": "TAKEDA-C13011", "Description": "A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction of Clinical Response and Remission by Vedolizumab in Patients With Moderate to Severe Crohn's Disease" },{ "PostingID": 2360, "Title": "UCB-C87031", "Description": "A Study to Test the Effect of CDP870 in the Treatment of Crohn's Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo)" },{ "PostingID": 2361, "Title": "UCB-C87032", "Description": "Study to Test the Effect of CDP870 in the Treatment of Crohn's Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo), Following 3 Doses of Active Drug (CDP870)." },{ "PostingID": 3918, "Title": "UCB-C87085", "Description": "Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Remission in Patients With Crohn's Disease" },{ "PostingID": 19757, "Title": "UCB-C87059", "Description": "A Phase IIIb Multicenter, Double-blind, Placebo-controlled,Randomized Trial to Examine the Corticosteroid-sparing Effect of Certolizumab Pegol in Patients With Moderate to Severe Crohn's Disease." }]